Treatment of Headache in the ED

Similar documents
Adult & Pediatric Patients. Stanford Health Care, Division Pain Medicine

Treating Headache Recurrence After Emergency Department Discharge: A Randomized Controlled Trial of Naproxen Versus Sumatriptan

Inpatient Treatment of Refractory Headache

ISSN doi: /head VC 2015 American Headache Society Published by Wiley Periodicals, Inc.

Dose: Metoclopramide -0.1 mg/kg (max 10 mg) IV, over 15 minutes

Disclosures. Triptans for Kids 5/16/13

Faculty Disclosures. Learning Objectives. Acute Treatment Strategies

PAIN MANAGEMENT AND SEDATION/ORIGINAL RESEARCH

Comparison of Intravenous Metoclopramide and Acetaminophen in Primary Headaches: a Randomized Controlled Trial

What A Headache! Theresa Biesiada March 8, 2012

Specific Care Question : Question Originator: Plain Language Summary from The Office of Evidence Based Practice: Conditional Recommendation

The best defense is a good offense. Optimizing the Acute Treatment of Migraine. Disclosures 11/10/2017

How do we treat migraine? New SIGN Guidelines

Treatment Of Medication. Overuse Headache

Chronic Migraine in Primary Care. December 11 th, 2017 Werner J. Becker University of Calgary

MIGRAINE UPDATE. Objectives & Disclosures. Learn techniques used to diagnose headaches. Become familiar with medications used for headache treatment.

HMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in

A synopsis of: Diagnosis and Management of Headaches in Adults: A national clinical guideline. Scottish intercollegiate Guidelines Network SIGN

Migraine Acute treatment

Building a Headache Infusion Program

Clinical Learning Days November 10, 2017

HEADACHE: Benign or Severe Dr Gobinda Chandra Roy

Migraine is a common recurrent neurological disorder with

Parenteral Dihydroergotamine for Acute Migraine Headache: A Systematic Review of the Literature

A case of a patient with chronic headache. Focus on Migraine. None related to the presentation Grants to conduct clinical trials from: Speaker bureau:

MIGRAINE A MYSTERY HEADACHE

HEADACHE. Dr Nick Pendleton. September Headache

Inpatient Treatment of Status Migraine With Dihydroergotamine in Children and Adolescents

Headaches in Pregnancy Before, During, and After

I. Migraine management in the Emergency Department

Drug Class Review Triptans

ADVANCES IN MIGRAINE MANAGEMENT

10/13/17. Christy M. Jackson, MD Director, Dalessio Headache Center Scripps Clinic, La Jolla Clinical Professor, Neurosciences UCSD

MEASURE #1: MEDICATION PRESCRIBED FOR ACUTE MIGRAINE ATTACK Headache

Abstract The aim of this prospective,

H-A-L-D-O-L Spells Relief

10/31/2017 PRIMARY CARE AND HEADACHE DISCLOSURES WHERE DO THOSE WITH HEADACHE SEEK MEDICAL CARE? Primary Care 67%

25/09/2018 HEADACHE. Dr Nick Pendleton

Clinical case. Clinical case 3/15/2018 OVERVIEW. Refractory headaches and update on novel treatment. Refractory headache.

Index. Prim Care Clin Office Pract 31 (2004) Note: Page numbers of article titles are in boldface type.

Chronic Daily Headaches

Headache A Practical Approach

COMBINATION THERAPIES PREVENTATIVE THERAPIES BETA BLOCKERS

Faculty Disclosure. Karen L. Bremer, MD. Dr. Bremer has listed no financial interest/arrangement that would be considered a conflict of interest.

Short Clinical Guidelines: Headache, Key Points for Diagnosis and Treatment

The 45-year-old woman with monthly headaches. Anne MacGregor Barts and the London School of Medicine and Dentistry

WORRIED ABOUT PAIN AFTER ORAL SURGERY?

MEASURE #4: Overuse of Barbiturate Containing Medications for Primary Headache Disorders Headache

Headaches in the Pediatric Emergency Dept

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

I have no financial relationships to disclose. I will not discuss investigational use of medication in my presentation.

Headache Master School Japan-Osaka 2016 (HMSJ-Osaka2016) October 23, II. Management of Refractory Headaches

What You Should Know About Your HEADACHE. Learn more about headache types, triggers, and treatments, when to get help, and how to help yourself

Optimizing Your Quality of Life During Cancer Treatment: Pain & Side Effect Management

Lasmiditan (200 mg and 100 mg) Compared to Placebo for Acute Treatment of Migraine

PAIN. TREATMENT TABLES Analgesics. NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose

Maternity. Migraine in pregnancy Information for women

Peri operative pain control. Disclosure. Objectives 9/1/2011. No current conflicts of interest

Drug Class Review Triptans

CONCERNED ABOUT TAKING OPIOIDS AFTER SURGERY?

Disclosures. Objectives 6/2/2017

Goals. Primary Headache Syndromes. One-Year Prevalence of Common Headache Disorders

Prednisone vs. placebo in withdrawal therapy following medication overuse headache

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Headache evaluation and management after concussion. Assistant Professor

Controversies in Migraine Management

The ALTO Program: A Strategy to Reduce Opioid use in the Emergency Department

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

11. HEADACHE 1. Pablo Lapuerta, MD, Steven Asch, MD, MPH, and Kenneth Clark, MD, MPH

Measure Components Numerator Statement

Controlling Migraine Pain

Iroquois Healthcare Association (IHA) Opioid Alternative Project. Clinician Training Materials

An Overview of MOH. ALAN M. Rapoport, M.D. Clinical Professor of Neurology The David Geffen School of Medicine at UCLA Los Angeles, California

Approach to the Workup and Management of Headache in the Emergency Department and Inpatient Settings

Migraine much more than just a headache

Management options for Migraine. Prof. Dr. Khwaja Nazimuddin Head Dept. of Internal Medicine BIRDEM

PHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 5/18/17 SECTION: DRUGS LAST REVIEW DATE: 5/17/18 LAST CRITERIA REVISION DATE: ARCHIVE DATE:

Managing Headache in Acute Medicine. Ben Lovell Consultant Physician in Acute Medicine University College London Hospital

Strategies in Migraine Care

MIGRAINE ASSOCIATION OF IRELAND

Acute Migraine Treatment. Morris Levin, MD Professor of Neurology Director, Headache Center UCSF Department of Neurology San Francisco, CA

HEADACHE 1 Pablo Lapuerta, M.D., and Steven Asch, M.D., M.P.H.

Can I send this headache patient home? Dr Nicola Giffin Consultant Neurologist Bath, Nov 2017

Migraine Migraine Age Specific Prevalence in the United States. Headache International Headache Society Classification

Acute Migraine Treatment: What you and your family should know to help you make the best choices with your doctor

Çiçek Wöber-Bingöl HEADACHE UNIT FOR CHILDREN AND ADOLESCENCE

disease or in clients who consume alcohol on a regular basis. bilirubin

Risk Factors, Clinical Course, and Barriers to Care in Adults and Pediatrics. Rebecca R. Buttaccio, PA-C Dent Neurologic Institute

OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA

Sean Kelcey CCPA EM PA Selkirk Regional Health Center Selkirk, MB CAPA 2017

UPDATE IN MIGRAINE MANAGEMENT

Understanding. Migraine. Amy, diagnosed in 1989, with her family.

Headache. Section 1. Migraine headache. Clinical presentation

Screening - inclusion criteria

PAEDIATRIC ACUTE CARE GUIDELINE. Headache. This document should be read in conjunction with this DISCLAIMER

Regulatory Status FDA approved indication: Migranal Nasal Spray is indicated for the acute treatment of migraine headaches with or without aura (1).

What is new in the migraine world! Modar Khalil Consultant neurologist Hull Royal Infirmary

The presenting and prescribing patterns of migraine in an Australian emergency department: A descriptive exploratory study

Improving Health, Enriching Life. Pain Management. Altru HEALTH SYSTEM

Pain Management Strategies Webinar/Teleconference

Transcription:

Treatment of Headache in the ED Benjamin W. Friedman, MD, MS, FAAEM Associate professor of Emergency Medicine Albert Einstein College of Medicine Montefiore Medical Center

Disclosure

Topics of Discussion 1) Why don t we use triptans in the ED (and should we?) 2) An ED specific nosology & the unobtainable goal of diagnostic clarity 3) Opioid wars: The frequent flyers

Why don t we use triptans in the ED Why don t we use triptans in the ED (and should we)?

Case 36y woman with typical headache x 18 hrs Started gradually at work yesterday Severe, occipital, bilateral, throbbing, with nausea. No relief with ibuprofen 800mg, naproxen 500mg, acetaminophen 1500mg, hydrocodone/ acetaminophen x 2 PMH: Migraine without aura; 3 previous ED visits for migraine Usually uses ibuprofen 2x/ month (with relief), PE: Unremarkable including normal cranial nerve exam, normal PE: Unremarkable including normal cranial nerve exam, normal visual acuity, and normal retinal exam

Treatment of migraine in US EDs Medication 2010 1998 Any parenteral opioid 53% 51% Meperidine 7% 37% Hydromorphone 26% <1% Morphine 10% 1% Ketorolac 34% 16% Promethazine 33% 27% Metoclopramide 17% 3% Prochlorperazine 15% 16% Any triptan 7% 10% Dihydroergotamine 1% 3% Dexamethasone 8% 0% Friedman, West, Vinson, et.al. Cephalalgia. 2014

Why don t EPs use triptans? Content with current practice: what I use works Lack of exposure- Don t know/ don t trust Contra-indications- 39% of ED HA patients with elevated BP at triage 1 Unknown pregnancy status Unknown risk for coronary heart disease Demanding patients Fear of side effects 1. Gupta M. AHS June, 2005

Sumatriptan 2hr relief Drug, dose # of studies # improved with triptan # improved with placebo NNT Sumatriptan, 6mg, SQ 8 379/477 (79%) 131/461 (28%) 2.0 (1.8, 2.2) Oldman, Pain, 2002

All the triptans- 2hr headache relief Oldman, Pain, 2002

Efficacy of sumatriptan Subcutaneous sumatriptan, 6mg Meaningful relief Time to meaningful relief (median) Suma 75% 34 min 67% Placebo 35% NA 92% 24 hour recurrence (in those with relief) Adverse effects: 52% of Suma group (vs 27% of placebo). Dizziness, vertigo, paresthesias. 5 reported tdchest ttightness, heaviness, or numbness Akpunonu BE. Ann Emerg Med 1995;25(4):464 9

Metoclopramide versus Sumatriptan 6mg SQ MCP (n=40) Suma (n=38) Sumatriptan 6mg SQ Metoclopramide 20mgIV q 30m +DPH 2hr pain free 59% 36% Could resume normal activities 85% 69% Friedman, Neurology, 2005

Metoclopramide versus Sumatriptan 6mg SQ MCP 10mg IV Vs Sumatriptan (n=40) 60 min pain free: MCP: 65% Suma: 45% NNT=5 Esteban Morales 1999 MCP 20mg IV Vs Sumatriptan (n=124) MCP improves on average 1.1 more than Suma (0-10 scale) Talabi. Journal of Research in Medical Sciences. 2013

IV prochlorperazine 10mg + diphenhydramine 12.5mg Vs. Subcutaneous sumatriptan 6mg The mean decrease in pain intensity it in the IV prochlorperazine with diphenhydramine group was 73 mm compared with 50 mm in the subcutaneous sumatriptan group (difference=23 mm; 95% CI 11 to 36 mm). Kostic, A Emerg Med, 2010

Droperidol Droperidol 2.75mg IM Droperidol 8.25mg IM Droperidol 5.5mg IM Droperidol 0.1mg IM Placebo Silberstein., Neurology, 2003. 2

Haloperidol 5mg IV versus placebo Includes those who did not respond to n=20 n=20 n=24 placebo and others who did not consent for RCT

Chlorpromazine 0.1 mg/kg g vs placebo Migraine without aura Placebo n=30 Chlorpromazine n=30 Migraine with aura Placebo n=30 Pain Free at 30 3% 21% 0 37% minutes Chlorpromazine n=30 Pain Free at 60 10% 63% 7% 67% minutes Pain free at 24 hours 47% 74% 73% 90% Bigal, Journal of EM, 2002

Treatment of migraine: anti-dopaminergics Underappreciated/ underutilized for migraine Extensive clinical evidence base for these medications as primary treatment of migraine (mostly parenteral). Clinical data has outpaced basic science

Anti-histamines? Sustained relief (48 hours) Diphenhydramine Placebo Difference (95%CI) 41/99 39/103 4% (41%) (38%) ( 10, 17%)

Adverse events AE Diphenhydramine h Placebo Difference (95%CI) Very restless 8/99 7/102 1% (8%) (7%) ( 6, 8%) More Benadryl 6/104 (6%) 8/ 103 (8%) 2% ( 5, 9%)

Dexamethasone Colman. BMJ. 2008

AHS: Management of Adults with Acute Migraine in the Emergency Department Intravenous metoclopramide and prochlorperazine, and subcutaneous sumatriptan should be offered to eligible adults who present to an ED with acute migraine (Should offer Level B) Dexamethasone should be offered to these patients to prevent recurrence of headache (Should offer Level B) Because of lack of evidence demonstrating efficacy and concern about sub-acute or long-term sequelae, injectable morphine and hydromorphone are best avoided as first-line therapy (May avoid--level C)

Case 36y woman with typical headache x 18 hrs Started gradually at work yesterday Severe, occipital, bilateral, throbbing, with nausea. No relief with ibuprofen 800mg, naproxen 500mg, sumatriptan 100mg x 2 Akathisia after previous treatment with metoclopramide PMH: Migraine without aura; 3 previous ED visits for migraine Usually uses ibuprofen 2x/ month (with relief) PE: Unremarkable including normal cranial nerve exam, normal visual acuity, and normal retinal exam

How I treat migraine 1. Metoclopramide 2. Dexamethasone 3. Metoclopramide + ketorolac 4. Metoclopramide + DHE 5. GONB 6. Percocet? MOH? Chronic migraine? Psychiatric co-morbidities

An ED specific nosology & the unobtainable An ED specific nosology & the unobtainable goal of diagnostic clarity

How should I treat this patient? 36 year female presents with acute exacerbation of recurrent headache disorder x 12 hours. Similar to previous. Never been given a specific diagnosis. No relief with Advil 600mg 12 hours ago. RoS otherwise negative. Physical exam is noncontributory. Patient A -Left frontal -Throbbing -Associated with nausea Patient B -Bifrontal -Pressure/ tightness -Associated with nausea Patient C -Bifrontal -Pressure/ tightness -No associated symptoms

Diagnostic clarity Badness: Tumor, aneurysm, meningitis Migraine Tension-type headache Sinus headache Hypertensive headache

Diagnostic reality A cohort study of 480 patients Friedman, Hochberg, Esses, etal Annals Emergency Medicine 2007

Treatment of primary headaches Diagnosis Treatment Treatment Diagnosis

Metoclopramide 10mg IV Migraine (n=50) Tension-type (n=35) Improvement after 45 minutes 85% 81% Needed rescue medication 14% 14% Cicek M, Karcioglu O, Parlak I, et.al. EMJ, 2004. 21(3): 323-6

Sumatriptan 6mg SQ Migraine Tension-type (n=84) (n= 18) Baseline pain score (0-100) 88 77 Improvement at 30 min 35% 38% Improvement at 60 min 57% 60% Miner, American Journal of Emergency Medicine, 2007

TTH Outcome Ketorolac Metoclopramide Difference 30mg IV 10mg (95%CI) Sustained freedom 9% 26% 17% (2, 32%) Friedman. Ann Emerg Med. 2013

TTH Medication Pain free 60 min Pain free 24 hours Chlorpromazine 0.1 mg/kg (n=30) 70% 87% Placebo (n=30) 20% 63% Bigal, Arq Neuropsiquiatr, 2002

How should I treat this patient? 36 year female Patient A -Left frontal -Throbbing -Associated with nausea Patient B -Bifrontal -Pressure/ tightness -Associated with nausea Patient C -Bifrontal -Pressure/ tightness -No associated symptoms Discuss differential diagnosis at time of discharge

Opioid wars & the Frequent Flyers

The case 36y woman, presents with her typical migraine headache 12 days of migraine/ month Sumatriptan and ibuprofen usually give relief 2 ED visits/ month for severe migraine refractory to oral treatment Presents with 10/10 severe pain for 6 hours Doc, just give me my Demerol

Opioids for treatment of headache in the ED The debate: Oligoanalgesia versus problematic behavior Oligoanalgesia: Underuse of analgesics in face of valid indication Problematic behavior: Drug-seeking and ED recidivism (inappropriate use of medical treatments and resources)

Reasons not to use opioids 1. Bouncebacks/ recidivism 2. Back to work 3. Chronification 4. Refractory to triptans Colman, Neurology, 2004; Bigal, Headache, 2008; Jakubowski, Headache, 2005; Ho, Headache, 2009

Therefore: 1. In opioid naïve patients: 2. In patients who request opioids: 3. In patients who insist on opioids: 4. In patients who frequently present to ED and insist on opioids:

Problematic patients Screen for interventions Outpatient provider Medication overuse headache Preventives Rule out secondary headache! Problematic patient committees Department wide policy/ Patient specific interventions to be implemented when the patient next returns to the ED Frequent visitor lists Treatment contracts

The case 36y woman, presents with her typical migraine headache 12 days of migraine/ month Sumatriptan and ibuprofen usually give relief 2 ED visits/ month for severe migraine refractory to oral treatment Presents with 10/10 severe pain for 6 hours Doc, just give me my Demerol

BWFriedmanMD@gmail.com